Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBP-426 in 2nd Line Gastric/Esophageal Cancer
NCT00964080Phase 2Unknown
- Sponsor
- Mebiopharm
- Start
- May 2009
- Primary completion
- Oct 2012
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of MBP-426 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Mebiopharm. Status: unknown.
02
Drugs
MBP-426
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00964080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964080.